

RECEIVED
CENTRAL FAX CENTER

JAN 31 2006

Attorney Docket No.: 6423.404-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al.

Serial No.: 10/602,838

Group Art Unit: 1651

Filed: June 24, 2003

Examiner: To be assigned

For: Liquid Composition of Factor VII Polypeptides

CERTIFICATE OF FACSIMILE TRANSMISSION
571-273-8300

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form 1449

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner To be assigned, fax number (571)-273-8300.

Respectfully submitted,

Date: January 31, 2006


Csaba Attila Szakolczai
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

RECEIVED
CENTRAL FAX CENTER

002/004

JAN 31 2006

Attorney Docket No.: 6423.404-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al.

Application No.: 10/602,838

Group Art Unit: 1651

Filed: June 24, 2003

Examiner: To be assigned

For: Liquid Composition of Factor VII Polypeptides

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith an additional reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than that listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. As the reference is a US patent, the reference can be found in the US PTO archives.

The reference is as follows:


1. US 5925738

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: January 31, 2006


Reza Green, Reg. No. 38,475
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE

FORM PTO-1449 (Rev. 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 6423.404-US	Serial No. 10/602,838
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Hansen et al.		
(Use several sheets if necessary)		Filing Date June 24, 2003	Group 1651	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.